USPTO serial 99505429
ALTAIRA
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SCHIMPF, TIMOTHY O
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ALTAIRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $449*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Waltham, MA, US
Waltham, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Keith Toms
Keith Toms McCarter & English, LLP265 Franklin StreetBoston, MA 02110United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Excipients for use in the manufacture of pharmaceutical preparations; Chemical additives for use in the manufacture of pharmaceutical preparations; Active chemical ingredients for use in the manufacture of pharmaceuticals | ACTIVE | — |
| 005 | Drug delivery agents in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of long-acting, extended release, or continuous release capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of organ rejection, namely, immunosuppressants; Pharmaceutical preparations for the treatment of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Antibiotics; Pharmaceutical preparations used in organ transplantation; Contraceptive preparations | ACTIVE | — |
| 042 | Pharmaceutical research and development; Scientific research; Medical research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of technology in the field of drug delivery; Research and development of technology in the field of long-acting, extended release, and continuous release drug delivery agents; Research and development of technology that facilitate the delivery of pharmaceutical preparations in the field of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings; Pharmaceutical research in the field of drug delivery agents; Pharmaceutical research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Pharmaceutical research in the field of excipients and pharmaceutical formulation; Pharmaceutical research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Medical and scientific research in the field of drug delivery agents; Medical and scientific research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Medical and scientific research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medical and scientific research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Medical and scientific research in the fields of organ rejection and immunosuppressants; Medical and scientific research in the field of excipients and pharmaceutical formulation; Medical and scientific research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Consulting services in the field of pharmaceutical research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nortiva Bio, Inc.
- Other trademarks owned by Nortiva Bio, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ALTAIRA
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 14, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 14, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 8, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 12, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 10, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 10, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 10, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 10, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 10, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 3, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 1, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 1, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 1, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 1, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 2, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 19, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 19, 2025 | NWAP | NEW APPLICATION ENTERED | — |